Thirant Cécile, Lopez Cécile, Malinge Sébastien, Mercher Thomas
INSERM U1170, Villejuif, France.
Gustave Roussy, Villejuif, France.
Mol Cell Oncol. 2017 Sep 26;4(6):e1345351. doi: 10.1080/23723556.2017.1345351. eCollection 2017.
The ETO2-GLIS2 fusion oncoprotein is associated with poor prognosis pediatric acute megakaryoblastic leukemia. Recently, we observed that ETO2-GLIS2 controls enhancers activity at genes regulating haematopoietic progenitor self-renewal and differentiation toward the megakaryocytic lineage. We also showed that targeting ETO2-GLIS2 complex stability inhibits these properties and may represent a novel therapeutic strategy.
ETO2-GLIS2融合癌蛋白与预后不良的小儿急性巨核细胞白血病相关。最近,我们观察到ETO2-GLIS2可控制调节造血祖细胞自我更新及向巨核细胞系分化的基因的增强子活性。我们还表明,靶向ETO2-GLIS2复合物稳定性可抑制这些特性,这可能代表一种新的治疗策略。